367 related articles for article (PubMed ID: 15050906)
1. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography.
Borah B; Dufresne TE; Chmielewski PA; Johnson TD; Chines A; Manhart MD
Bone; 2004 Apr; 34(4):736-46. PubMed ID: 15050906
[TBL] [Abstract][Full Text] [Related]
2. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.
Borah B; Ritman EL; Dufresne TE; Jorgensen SM; Liu S; Sacha J; Phipps RJ; Turner RT
Bone; 2005 Jul; 37(1):1-9. PubMed ID: 15894527
[TBL] [Abstract][Full Text] [Related]
3. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.
Borah B; Dufresne TE; Ritman EL; Jorgensen SM; Liu S; Chmielewski PA; Phipps RJ; Zhou X; Sibonga JD; Turner RT
Bone; 2006 Aug; 39(2):345-52. PubMed ID: 16571382
[TBL] [Abstract][Full Text] [Related]
4. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography.
Dufresne TE; Chmielewski PA; Manhart MD; Johnson TD; Borah B
Calcif Tissue Int; 2003 Nov; 73(5):423-32. PubMed ID: 12964065
[TBL] [Abstract][Full Text] [Related]
5. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis.
Dalle Carbonare L; Arlot ME; Chavassieux PM; Roux JP; Portero NR; Meunier PJ
J Bone Miner Res; 2001 Jan; 16(1):97-103. PubMed ID: 11149495
[TBL] [Abstract][Full Text] [Related]
6. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
[TBL] [Abstract][Full Text] [Related]
7. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
Recker RR; Delmas PD; Halse J; Reid IR; Boonen S; GarcĂa-Hernandez PA; Supronik J; Lewiecki EM; Ochoa L; Miller P; Hu H; Mesenbrink P; Hartl F; Gasser J; Eriksen EF
J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
[TBL] [Abstract][Full Text] [Related]
8. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
Ste-Marie LG; Sod E; Johnson T; Chines A
Calcif Tissue Int; 2004 Dec; 75(6):469-76. PubMed ID: 15478000
[TBL] [Abstract][Full Text] [Related]
9. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.
Recker RR; Bare SP; Smith SY; Varela A; Miller MA; Morris SA; Fox J
Bone; 2009 Jan; 44(1):113-9. PubMed ID: 18983947
[TBL] [Abstract][Full Text] [Related]
10. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.
Zoehrer R; Roschger P; Paschalis EP; Hofstaetter JG; Durchschlag E; Fratzl P; Phipps R; Klaushofer K
J Bone Miner Res; 2006 Jul; 21(7):1106-12. PubMed ID: 16813531
[TBL] [Abstract][Full Text] [Related]
11. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography.
Borah B; Dufresne TE; Chmielewski PA; Gross GJ; Prenger MC; Phipps RJ
J Bone Miner Res; 2002 Jul; 17(7):1139-47. PubMed ID: 12096826
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
[TBL] [Abstract][Full Text] [Related]
13. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
[TBL] [Abstract][Full Text] [Related]
14. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
Durchschlag E; Paschalis EP; Zoehrer R; Roschger P; Fratzl P; Recker R; Phipps R; Klaushofer K
J Bone Miner Res; 2006 Oct; 21(10):1581-90. PubMed ID: 16995813
[TBL] [Abstract][Full Text] [Related]
15. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
Bahlous A; Bouzid K; Sahli H; Sallami S; Abdelmoula J
Tunis Med; 2009 Jun; 87(6):380-1. PubMed ID: 19927782
[TBL] [Abstract][Full Text] [Related]
16. Vertebral fractures are associated with increased cortical porosity in iliac crest bone biopsy of men with idiopathic osteoporosis.
Ostertag A; Cohen-Solal M; Audran M; Legrand E; Marty C; Chappard D; de Vernejoul MC
Bone; 2009 Mar; 44(3):413-7. PubMed ID: 19071239
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of changes in trabecular bone architecture and mechanical properties of minipig vertebrae by three-dimensional magnetic resonance microimaging and finite element modeling.
Borah B; Dufresne TE; Cockman MD; Gross GJ; Sod EW; Myers WR; Combs KS; Higgins RE; Pierce SA; Stevens ML
J Bone Miner Res; 2000 Sep; 15(9):1786-97. PubMed ID: 10976998
[TBL] [Abstract][Full Text] [Related]
18. Early estrogen replacement therapy reverses the rapid loss of trabecular bone volume and prevents further deterioration of connectivity in the rat.
Lane NE; Haupt D; Kimmel DB; Modin G; Kinney JH
J Bone Miner Res; 1999 Feb; 14(2):206-14. PubMed ID: 9933474
[TBL] [Abstract][Full Text] [Related]
19. Sequential treatment of ovariectomized mice with bFGF and risedronate restored trabecular bone microarchitecture and mineralization.
Yao W; Balooch G; Balooch M; Jiang Y; Nalla RK; Kinney J; Wronski TJ; Lane NE
Bone; 2006 Sep; 39(3):460-9. PubMed ID: 16713415
[TBL] [Abstract][Full Text] [Related]
20. Risedronate reduces intracortical porosity in women with osteoporosis.
Borah B; Dufresne T; Nurre J; Phipps R; Chmielewski P; Wagner L; Lundy M; Bouxsein M; Zebaze R; Seeman E
J Bone Miner Res; 2010 Jan; 25(1):41-7. PubMed ID: 19580469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]